GLP-1 Receptor Agonists: Effects on Cardiovascular Risk ReductionLORBER, Daniel.Cardiovascular therapeutics (Print). 2013, Vol 31, Num 4, pp 238-249, issn 1755-5914, 12 p.Article

Glucagon-Like Peptide-1 Receptor Agonist Administration Suppresses Both Water and Saline Intake in RatsMCKAY, N. J; DANIELS, D.Journal of neuroendocrinology. 2013, Vol 25, Num 10, pp 929-938, issn 0953-8194, 10 p.Article

Le liraglutideGERSON, Michel.Médecine (Montrouge). 2010, Vol 6, Num 7, pp 302-305, issn 1777-2044, 4 p.Article

Detection of Adverse Drug Reactions Among Ordinary Users of Liraglutide on the Occasion of Drug Dispensing in the Community Pharmacy SettingCHRISTENSEN, Søren Troels; BJERRUM, Ole Jannik.Journal of patient safety. 2013, Vol 9, Num 4, pp 219-223, issn 1549-8417, 5 p.Article

Incretin mimetics as emerging treatments for type 2 diabetesJOY, Scott V; RODGERS, Philip T; SCATES, Ann C et al.The Annals of pharmacotherapy. 2005, Vol 39, Num 1, pp 110-118, issn 1060-0280, 9 p.Article

Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4KANOSKI, Scott E; FORTIN, Samantha M; ARNOLD, Myrtha et al.Endocrinology (Philadelphia). 2011, Vol 152, Num 8, pp 3103-3112, issn 0013-7227, 10 p.Article

Liraglutide in combination with acitretin for severe recalcitrant psoriasisREID, C. T; TOBIN, A. M; AHERN, T et al.British journal of dermatology (1951). 2013, Vol 169, Num 1, pp 230-231, issn 0007-0963, 2 p.Article

Tritium labelling of the GLP-1 analogue liraglutideLARSEN, Uffe S; HANSEN, Heidi B; DAHL, Anne-Mette et al.Journal of labelled compounds & radiopharmaceuticals. 2007, Vol 50, Num 5-6, pp 549-550, issn 0362-4803, 2 p.Conference Paper

The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodentsEGECIOGLU, Emil; STEENSLAND, Pia; FREDRIKSSON, Ida et al.Psychoneuroendocrinology. 2013, Vol 38, Num 8, pp 1259-1270, issn 0306-4530, 12 p.Article

Pancreatitis: A Potential Complication of Liraglutide?FRANKS, Andrea S; LEE, Phillip H; GEORGE, Christa M et al.The Annals of pharmacotherapy. 2012, Vol 46, Num 11, pp 1547-1553, issn 1060-0280, 7 p.Article

Noninsulin Treatment of Type 2 Diabetes Mellitus in Geriatric Patients: A ReviewGERMINO, F. Wilford.Clinical therapeutics. 2011, Vol 33, Num 12, pp 1868-1882, issn 0149-2918, 15 p.Article

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetesNAUCK, M. A; HOMPESCH, M; FILIPCZAK, R et al.Experimental and clinical endocrinology & diabetes. 2006, Vol 114, Num 8, pp 417-423, issn 0947-7349, 7 p.Article

Clinical Studies of Liraglutide, a Novel, Once-Daily Human Glucagon-Like Peptide-1 Analog for Improved Management of Type 2 Diabetes MellitusDRAB, Scott R.Pharmacotherapy. 2009, Vol 29, Num 12, issn 0277-0008, 43S-54S, 2Article

Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestionROTONDO, A; JANSSEN, P; MULE, F et al.International journal of obesity. 2013, Vol 37, Num 5, pp 693-698, issn 0307-0565, 6 p.Article

Incretin hormones and the satiation signalHOLST, J. J.International journal of obesity. 2013, Vol 37, Num 9, pp 1161-1168, issn 0307-0565, 8 p.Article

Dérivés du GLP-1 et inhibiteurs de la DPP-IV : perspectives dans le traitement du diabète de type 2 = GLP-1 derivatives and dipeptidyl peptidase IV inhibitor in the treatment of type 2 diabetesBLICKLE, Jean-Frédéric.STV. Sang thrombose vaisseaux. 2006, Vol 18, Num 5, pp 265-269, issn 0999-7385, 5 p.Article

Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes MellitusSCOTT, Lesley J.Drugs (Basel). 2014, Vol 74, Num 18, pp 2161-2174, issn 0012-6667, 14 p.Article

Liraglutide as additional treatment for type 1 diabetesVARANASI, Ajay; BELLINI, Natalie; RAWAL, Deepti et al.European journal of endocrinology. 2011, Vol 165, Num 1, pp 77-84, issn 0804-4643, 8 p.Article

Liraglutide, a Long-Acting Human Glucagon-Like Peptide 1 Analog, Improves Glucose Homeostasis in Marginal Mass Islet Transplantation in MiceMERANI, S; TRUONG, W; EMAMAULLEE, J. A et al.Endocrinology (Philadelphia). 2008, Vol 149, Num 9, pp 4322-4328, issn 0013-7227, 7 p.Article

Improved glycemic control with no weight increase n patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog Liraglutide (NN221): A 12-week, double-blind, randomized, controlled trialMADSBAD, Sten; SCHMITZ, Ole; RANSTAM, Jonas et al.Diabetes care. 2004, Vol 27, Num 6, pp 1335-1342, issn 0149-5992, 8 p.Article

Use of exenatide and liraglutide in Denmark: a drug utilization studyPOTTEGARD, Anton; BJERREGAARD, Bine Kjøller; LARSEN, Michael Due et al.European journal of clinical pharmacology. 2014, Vol 70, Num 2, pp 205-214, issn 0031-6970, 10 p.Article

Effects of Liraglutide on β-Cell-Specific Glucokinase-Deficient Neonatal MiceSHIRAKAWA, Jun; TANAMI, Ritsuko; TOGASHI, Yu et al.Endocrinology (Philadelphia). 2012, Vol 153, Num 7, pp 3066-3075, issn 0013-7227, 10 p.Article

Liraglutide (victoza^®): place d'un nouvel analogue du GLP-1 dans le traitement du diabète de type 2BUYSSCHAERT, M; PREUMONT, V.Louvain médical. 2010, Vol 129, Num 8, pp 296-301, issn 0024-6956, 6 p.Article

Porcine Marginal Mass Islet Autografts Resist Metabolic Failure Over Time and Are Enhanced by Early Treatment with LiraglutideEMAMAULLEE, Juliet A; MERANI, Shaheed; BONNER-WEIR, Susan et al.Endocrinology (Philadelphia). 2009, Vol 150, Num 5, pp 2145-2152, issn 0013-7227, 8 p.Article

Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetesROSS, Stuart A; BALLANTINE, Jane.Current medical research and opinion. 2013, Vol 29, Num 12, pp 1617-1626, issn 0300-7995, 10 p.Article